-
Hydroxychloroquine Sulfate Workflow Guide
2026-09-07
Hydroxychloroquine Sulfate (SKU B4874) provides an aqueous research reagent for examining autophagy pathway modulation and TLR7/9-associated immune responses in autoimmune disease research. It is suitable for locally validated cellular and animal workflows, but not for DMSO- or ethanol-based stocks or long-term storage of prepared solutions.
-
Y-27632: From Cytoskeletal Control to Translation
2026-09-05
Y-27632 offers translational researchers a reversible, selective way to interrogate ROCK-dependent cytoskeletal state while separating mechanical effects from MEK/ERK–c-Myc:MAX regulation of TERT in human pluripotent stem cells. This article presents a practical framework for experimental validation, model selection, and responsible interpretation across stem cell and cancer biology research.
-
AO/PI Staining Solution: 5 Lab Scenarios
2026-09-04
This scenario-driven guide explains how AO/PI Staining Solution (SKU K2269) supports accurate live dead cell discrimination, fluorescence-based cell counting, and cytotoxicity workflows. It connects membrane-integrity measurements with practical assay design, storage, interpretation, and vendor-selection decisions.
-
Bay 11-7821: NF-κB Assay Design in Tumor Immunology
2026-09-04
Bay 11-7821 (BAY 11-7082) offers a mechanistic way to test how IKK–NF-κB signaling shapes macrophage–T-cell interactions in cancer research. This article translates recent radiotherapy and checkpoint-blockade findings into rigorous assay decisions without overstating what a chemical inhibitor can prove.
-
Ruxolitinib Workflows for JAK-STAT Research
2026-09-03
Ruxolitinib (INCB018424) combines nanomolar JAK1/JAK2 activity with practical utility in progenitor, myelofibrosis, and immune-oncology assays. This guide translates pathway inhibition into reproducible dosing, phospho-signaling, colony, and high-dimensional spectral-flow workflows while separating established evidence from cross-domain experimental opportunities.
-
GSH-Responsive MOF Nanoparticles for Melanoma Therapy
2026-09-03
Hao and colleagues developed ICG-MOF-SS-AUNP12, a glutathione-responsive metal-organic framework nanoparticle that combines photothermal ablation with localized PD-1/PD-L1 blockade. The study shows how 808 nm irradiation, redox-triggered peptide release, and immune activation can be integrated into one melanoma-oriented nanoplatform, while also highlighting the validation needed before substituting related dyes such as IR-820.
-
4-Hydroxytamoxifen: Protocol and QC Guide
2026-09-02
4-Hydroxytamoxifen is a DMSO-compatible estrogen receptor modulator for controlled cell, cancer, cardiac myocyte, and selected mouse-model workflows. It should not be selected for protocols requiring water or ethanol as the primary solvent, and long-term storage of prepared solutions should be avoided.
-
CDK9 inhibitor A3294: Practical Workflow Guide
2026-09-02
CDK9 inhibitor A3294 provides a selective serine/threonine kinase inhibitor for examining CDK9-dependent transcription elongation, P-TEFb activity, and exploratory HIV-1 propagation assays. The available evidence is limited to the product dossier, so it should be validated in the intended assay and should not be treated as a pan-CDK reagent, universal cytotoxicity control, or therapeutic predictor.
-
Leupeptin: Precision Protease Control in Translation
2026-09-01
Leupeptin hemisulfate salt is more than a conventional protease-blocking reagent. Its reversible, competitive mechanism provides a controllable way to interrogate protein degradation, autophagy, and selected viral replication workflows, while a modern TET2 metabolite-binding protocol offers a useful model for orthogonal validation and translational assay design.
-
RepSox: ALK5 Inhibition in iPSC Workflows
2026-09-01
RepSox is a potent and selective ALK5 inhibitor for studying TGF-β signaling, induced pluripotent stem cell reprogramming, and cell differentiation. Its reported 4 nM ALK5 inhibition supports pathway-focused experiments, but current hiPSC-derived platelet benchmarks do not establish RepSox as a validated platelet-differentiation reagent.
-
Liproxstatin-1 in Ferroptosis Assay Design
2026-08-31
Liproxstatin-1 is a potent ferroptosis inhibitor for testing whether lipid peroxidation drives cell injury. This guide connects its validated rescue profile with a sex-specific salivary gland study and offers a causal, tissue-aware assay strategy.
-
0.4% Trypan Blue Solution: Practical Guide
2026-08-31
0.4% Trypan Blue Solution supports rapid cell viability measurement by differentiating unstained viable cells from blue-stained dead or membrane-damaged cells during cell counting. It is suitable for research workflows and cytotoxicity assays, but it should not be used for diagnostic purposes or as a standalone method for mechanistic apoptosis and necrosis detection.
-
Primary Antibody Dilution Buffer for PCNSL
2026-08-30
Learn how Primary Antibody Dilution Buffer supports spatial validation of PCNSL metabolic discoveries. This article connects single-cell evidence on SLC2A5 with practical IHC, ICC, and antibody-dependent ISH assay design.
-
Novobiocin: From Mechanism to Translation
2026-08-29
A translational strategy for using Novobiocin as a mechanistically rich aminocoumarin antibiotic across antibacterial resistance research, parasitic disease, antiviral discovery, and apoptosis-focused workflows.
-
Complete Nicotine Biosynthesis: A Vacuolar Metabolon
2026-08-28
Chang et al. resolve the final steps of nicotine biosynthesis by identifying a glycosylation-dependent, stereoselective Mannich-like condensation and a vacuolar five-component metabolon that coordinates pathway chemistry with transport. The study combines omics, biochemical reconstitution, pathway perturbation, and heterologous plant engineering to establish a transferable framework for nicotine production and pest-resistance research.